{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:19:04Z","timestamp":1747196344105,"version":"3.40.5"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Although eliminating HCV can prevent hepatocellular carcinoma (HCC), some patients develop HCC even after obtaining sustained virologic response (SVR). Previously, we developed a new formula to predict advanced liver fibrosis. This study aimed to clarify the usefulness of this formula for predicting HCC after achieving SVR. Among 351 consecutive patients who had been treated with direct-acting antivirals, 299 were included in this study. New formula scores were used as a marker for predicting liver fibrosis and as a predictive model for HCC incidence. The participants were 172 men and 127 women with a median age of 68 years. The median new formula score was -1.291. The cumulative HCC incidence rates were 4.3%, 9.7%, and 12.5% at 1, 3, and 5 years, respectively. The cumulative incidence of HCC was significantly higher in patients with a history of HCC than in those without treatment history of HCC (P = 2.52\u00d710<jats:sup>\u221226<\/jats:sup>). Multivariate analysis revealed that male (HR = 6.584, 95% CI = 1.291\u201333.573, P = 0.023) and new formula score (HR = 1.741, 95% CI = 1.041\u20132.911, P = 0.035) were independent factors associated with the development of HCC in patients without a treatment history of HCC. The optimal cutoff value for predicting the development of HCC was -0.214. The cumulative incidence rates of HCC in patients with new formula scores \u2265-0.214 were 5.4%, 15.3%, and 15.3% at 1, 3, and 5 years, respectively, whereas the incidence rates of HCC in patients with new formula scores &lt;-0.214 were 0.0%, 0.6%, and 4.8%, respectively (P = 2.12\u00d710<jats:sup>\u22124<\/jats:sup>). In conclusion, this study demonstrated the usefulness of new formula scores as a predictor of HCC after achieving SVR, especially in patients without past treatment history of treatment for HCC.<\/jats:p>","DOI":"10.1371\/journal.pone.0292019","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:44:47Z","timestamp":1695318287000},"page":"e0292019","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C"],"prefix":"10.1371","volume":"18","author":[{"given":"Yuji","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-7111","authenticated-orcid":true,"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisa","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michika","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Shioda-Koyano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadamichi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Korenobu","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeang","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Itokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"pone.0292019.ref001","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"PY Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"pone.0292019.ref002","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis","volume":"373","author":"MP Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0292019.ref003","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00535-016-1285-y","article-title":"The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II\/III study","volume":"52","author":"H Kumada","year":"2017","journal-title":"J Gastroenterol"},{"key":"pone.0292019.ref004","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/jgh.14447","article-title":"Efficacy and safety of elbasvir\/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study","volume":"34","author":"M Atsukawa","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0292019.ref005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hepr.12910","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir in dialysis patients with genotype 1b chronic hepatitis C","volume":"47","author":"M Atsukawa","year":"2017","journal-title":"Hepatol Res"},{"key":"pone.0292019.ref006","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.dld.2017.04.012","article-title":"Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C","volume":"49","author":"M Atsukawa","year":"2017","journal-title":"Dig Liver Dis"},{"key":"pone.0292019.ref007","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1272\/jnms.JNMS.2021_88-316","article-title":"Development of Interferon-Free, Direct-Acting Antivirals Treatment for Japanese Patients with Chronic Hepatitis C Infection and Chronic Kidney Disease","volume":"88","author":"M Atsukawa","year":"2021","journal-title":"J Nippon Med Sch"},{"key":"pone.0292019.ref008","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/apt.15218","article-title":"The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study","volume":"49","author":"M Atsukawa","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0292019.ref009","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/hepr.13739","article-title":"Time-course changes in liver functional reserve after successful sofosbuvir\/velpatasvir treatment in patients with decompensated cirrhosis","volume":"52","author":"M Atsukawa","year":"2022","journal-title":"Hepatol Res"},{"key":"pone.0292019.ref010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents","volume":"155","author":"V Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"pone.0292019.ref011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents","volume":"71","author":"F Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"pone.0292019.ref012","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores","volume":"157","author":"GN Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"pone.0292019.ref013","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12072-019-09939-2","article-title":"Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study","volume":"13","author":"T Ide","year":"2019","journal-title":"Hepatol Int"},{"key":"pone.0292019.ref014","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00535-020-01715-6","article-title":"Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs","volume":"55","author":"M Nakagawa","year":"2020","journal-title":"J Gastroenterol"},{"key":"pone.0292019.ref015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MEG.0000000000002479","article-title":"Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection","volume":"35","author":"N Ideno","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"pone.0292019.ref016","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MEG.0000000000000105","article-title":"Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C","volume":"26","author":"M Atsukawa","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"pone.0292019.ref017","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/apt.14380","article-title":"Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment","volume":"47","author":"E Ogawa","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0292019.ref018","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"H Nagata","year":"2017","journal-title":"J Hepatol"},{"key":"pone.0292019.ref019","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.14256","article-title":"Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study","volume":"46","author":"G Cabibbo","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0292019.ref020","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00535-021-01845-5","article-title":"Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis","volume":"57","author":"Y Tahata","year":"2022","journal-title":"J Gastroenterol"},{"issue":"9","key":"pone.0292019.ref021","doi-asserted-by":"crossref","first-page":"e0257166","DOI":"10.1371\/journal.pone.0257166","article-title":"A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C","volume":"16","author":"M Atsukawa","year":"2021","journal-title":"PLoS One"},{"key":"pone.0292019.ref022","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s12072-022-10336-5","article-title":"The best predictive model for post-SVR HCC: can it be universal?","volume":"16","author":"H Toyoda","year":"2022","journal-title":"Hepatol Int"},{"key":"pone.0292019.ref023","first-page":"775","article-title":"JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis","volume":"50","journal-title":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Hepatol Res"},{"key":"pone.0292019.ref024","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","article-title":"\u03b1-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C","volume":"58","author":"Y Asahina","year":"2013","journal-title":"Hepatology"},{"key":"pone.0292019.ref025","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/hep.26087","article-title":"Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C","volume":"57","author":"Y Arase","year":"2013","journal-title":"Hepatology"},{"key":"pone.0292019.ref026","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"HB El-Serag","year":"2016","journal-title":"Hepatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:45:08Z","timestamp":1695318308000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292019"}},"subtitle":[],"editor":[{"given":"Tyng-Yuan","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0292019","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}